Brands of Paracetamol /Caffeine in Kenya
Curamol plus, Dawa Limited
Napa Extra , Beximco Pharmaceuticals Ltd.
Painotab , Cosmos Limited
Panadol Extra, GSK
Panadol Extra with Optizorb, GlaxoSmithKline Kenya Limited
Sonamol Extra, Orange Pharma Ltd
Sonadol Extra , Orange Pharma Ltd
MODE OF ACTION:
The combination of paracetamol and caffeine is a well established analgesic combination.
INDICATIONS
This is recommended for the treatment of most painful and febrile conditions, for example, headache, including migraine, backache, toothache, rheumatic pain and dysmenorrhoea, and relief of the symptoms of colds, influenza and sore throat.
CONTRAINDICATIONS
Hypersensitivity to paracetamol, caffeine or any of the other constituents.
The speed of absorption of paracetamol may be increased by metoclopramide or domperidone and absorption reduced by colestyramine. The anticoagulant effect of warfarin and other coumarins may be enhanced by prolonged regular daily use of paracetamol with increased risk of bleeding; occasional doses have no significant effect.
DRUG INTERACTIONS:
The speed of absorption of paracetamol may be increased by metoclopramide or domperidone and absorption reduced by colestyramine. The anticoagulant effect of warfarin and other coumarins may be enhanced b
ADVERSE EFFECTS:
Blood and lymphatic system disorders
Thrombocytopenia Agranulocytosis
Immune system disorders
Anaphylaxis
Cutaneous hypersensitivity reactions including skin rashes, angiodema and Stevens Johnson syndrome/toxic epidermal necrolysis
Respiratory, thoracic and mediastinal disorders
Bromchospasm*
Hepatobiliary disorders
Hepatic dysfunction
* There have been cases of bronchospasm with paracetamol, but these are more likely in asthmatics sensitive to aspirin or other NSAIDs.
Caffeine
Central Nervous system
Nervousness Dizziness
When the recommended paracetamol-caffeine dosing regimen is combined with dietary caffeine intake, the resulting higher dose of caffeine may increase the potential for caffeine-related adverse effects such as insomnia, restlessness, anxiety, irritability, headaches, gastrointestinal disturbances and palpitations.
Reporting of suspected adverse reactions:
The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, pv@pharmacyboardkenya.org or clicking below button:
Paracetamol /Caffeine in Kenya
Paracetamol /Caffeine in Kenya
Paracetamol /Caffeine in Kenya
Paracetamol /Caffeine in Kenya
Clinical | Pharmacokinetic data
Pregnancy Category: Paracetamol-caffeine is not recommended for use during pregnancy due to the possible increased risk of lower birth weight and spontaneous abortion associated with caffeine consumption.
Routes of Administration: Oral
Bioavailability: Not Available
Protein Binding: Not Available
Metabolosim: Not Available
Onset of Action: Not Available
Elimination Half life: Not Available
Excretion: Not Available
Legal Status | Dosage forms & Strengths
Prescription Category:
OTC / Rx-only
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This drug is not a controlled substance under Narcotic Drugs and Psychotropic Substances (Control ) Act
Dosage Forms | Strengths:
Drug Indentifiers:
Paracetamol:
| CAS Number | |
|---|---|
| PubChem CID | |
| PubChem SID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | |
Caffeine:
| CAS Number | |
|---|---|
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | |
Drug Images
References/ Citation:
- Wojcicki, J., et al. “A double-blind comparative evaluation of aspirin, paracetamol and paracetamol+ caffeine (finimal) for their analgesic effectiveness.” Archivum immunologiae et therapiae experimentalis 25.2 (1977): 175.
- Esmaoglu, Aliye, Hatice Akpinar, and Fatih UÄŸur. “Oral multidose caffeine-paracetamol combination is not effective for the prophylaxis of postdural puncture headache.” Journal of clinical anesthesia 17.1 (2005): 58-61.